SkinBioTherapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2016 - 2019
Operating Revenue	1.21	0.13	0.07	-	-	Upgrade
Revenue	1.21	0.13	0.07	-	-	Upgrade
Revenue Growth (YoY)	815.26%	76.64%	-	-	-	Upgrade
Cost of Revenue	0.53	0.05	0.03	-	-	Upgrade
Gross Profit	0.68	0.09	0.05	-	-	Upgrade
Selling, General & Admin	3.03	2.15	2.17	0.99	0.98	Upgrade
Research & Development	0.56	0.93	0.86	0.51	0.64	Upgrade
Operating Expenses	3.59	3.08	3.03	1.5	1.62	Upgrade
Operating Income	-2.91	-3	-2.98	-1.5	-1.62	Upgrade
Interest Expense	-0.04	-0.01	-0.01	-0	-	Upgrade
Pretax Income	-2.95	-3.01	-2.99	-1.5	-1.62	Upgrade
Income Tax Expense	-0.07	-0.17	-0.2	-0.07	-0.12	Upgrade
Net Income	-2.88	-2.84	-2.79	-1.43	-1.5	Upgrade
Net Income to Common	-2.88	-2.84	-2.79	-1.43	-1.5	Upgrade
Shares Outstanding (Basic)	186	165	157	147	128	Upgrade
Shares Outstanding (Diluted)	186	165	157	147	128	Upgrade
Shares Change (YoY)	13.10%	5.06%	6.87%	14.53%	4.95%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.02	-0.01	-0.01	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.02	-0.01	-0.01	Upgrade
Free Cash Flow	-2.74	-2.73	-2.67	-1.56	-0.89	Upgrade
Free Cash Flow Per Share	-0.01	-0.02	-0.02	-0.01	-0.01	Upgrade
Gross Margin	56.51%	64.51%	60.64%	-	-	Upgrade
Operating Margin	-240.36%	-2271.26%	-3988.83%	-	-	Upgrade
Profit Margin	-237.95%	-2146.91%	-3735.37%	-	-	Upgrade
Free Cash Flow Margin	-226.80%	-2071.02%	-3575.44%	-	-	Upgrade
EBITDA	-2.77	-2.99	-2.98	-1.5	-1.61	Upgrade
EBITDA Margin	-229.38%	-	-	-	-	Upgrade
D&A For EBITDA	0.13	0.01	0	0	0.01	Upgrade
EBIT	-2.91	-3	-2.98	-1.5	-1.62	Upgrade
EBIT Margin	-240.36%	-	-	-	-	Upgrade

Updated Dec 10, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.